Suggested remit: To appraise the clinical and cost effectiveness of upadacitinib within its marketing authorisation for treating moderate to severe atopic dermatitis in people aged 12 and over.
- Status:
- Discontinued
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 3733
Project Team
- Project lead
- Shonagh D'Sylva
Email enquiries
If you have any queries please email TAteam2@nice.org.uk
Stakeholders
- Companies sponsors
- AbbVie (upadacitinib)
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- British Association of Dermatologists
- British Society for Allergy & Clinical Immunology
- Royal College of Physicians
- Professional groups
- Allergy UK
- National Eczema Society
- Comparator companies
- Accord (azathioprine, methotrexate, mycophenolate mofetil) – not participating
- Advanz Pharma (methotrexate) – not participating
- Aspen (azathioprine) – not participating
- Cipla (methotrexate) – not participating
- Dexcel-Pharma Limited (ciclosporin) – not participating
- Ennogen (alitretion, azathioprine) – not participating
- GlaxoSmithKline (alitretion) – not participating
- Hospira (methotrexate) – not participating
- Medac (methotrexate) – not participating
- Mylan (azathioprine, ciclosporin, mycophenolate mofetil) – not participating
- Nordic Pharma (methotrexate) – not participating
- Novartis Pharmaceuticals (ciclosporin, mycophenolate mofetil)
- Orion Pharma (methotrexate) – not participating
- Pfizer (methotrexate)
- Roche (mycophenolate mofetil) – not participating
- Rosemont Pharmaceuticals (methotrexate) – not participating
- Sandoz (methotrexate, mycophenolate mofetil) – not participating
- Sanofi (dupilumab)
- Santen (ciclosporin) – not participating
- Teva (mycophenolate mofetil) – not participating
- Therakind (methotrexate) – not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 August 2021 | Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960]. |
| 05 August 2021 | Suspended. Due to significant capacity challenges NICE has paused the development of the Single Technology Appraisals for [ID3768] abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over, [ID3733] Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over and [ID3734] Tralokinumab for treating moderate to severe atopic dermatitis. All 3 topics will be appraised together as a Multiple Technology Appraisal under [ID3960]. |
| 05 August 2021 | Discontinued |
| 21 July 2021 | Schedule affected by COVID-19. We are continuing to face significant capacity challenges and will be delaying the development of upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022 . |
| 21 July 2021 | We are continuing to face significant capacity challenges and will be delaying the development of upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]. This topic will now be considered as part of a multiple technology appraisal. We anticipate that it will be considered by the technology appraisal committee in early 2022. |
| 10 December 2020 | Invitation to participate |
| 10 December 2020 | In progress. Final scope issued |
| 16 July 2020 - 13 August 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual